Effect of phospholipase A$_2$ inhibitors during infection caused by *Leishmania (Leishmania) amazonensis*

Maria L. A. C. Bordon$^{1,3}$, Márcia D. Laurenti$^1$, Susan Pereira Ribeiro$^2$, Marcos H. Toyama$^3$, Daniela de O. Toyama$^4$ and Luiz Felipe D. Passero$^3$

**Abstract**

**Background:** Lipid metabolites play an important role in parasite differentiation and virulence. Studies have revealed that *Leishmania* sp. uses prostaglandins to evade innate barriers, thus enabling the parasites to survive inside immune cells. Despite the role of the enzyme Phospholipase A$_2$ (PLA$_2$) in prostaglandins production, few studies have investigated the role of parasite PLA$_2$ during the interaction between *L. (L.) amazonensis* and the host (in vitro and in vivo) immune cells.

**Methods:** In the present work, the leishmanicidal effect of PLA$_2$ inhibitors, methyl arachidonyl fluorophosphonate (MAFP), bromoenol lactone (BEL) and aristolochic acid (AA) were investigated in vitro (promastigote and intracellular amastigote forms of *L. (L.) amazonensis*) and during in vivo infection using BALB/c mice.

**Results:** The aforementioned inhibitors were deleterious to promastigote and amastigote forms of the *L. (L.) amazonensis* and were non-toxic to peritoneal macrophages from BALB/c mice. *L. (L.) amazonensis*-infected BALB/c mice treated with the inhibitor BEL presented decreased lesion size and skin parasitism; however, BEL treatment induced hepatotoxicity in BALB/c mice.

**Conclusions:** Results presented herein suggested that PLA$_2$ inhibitors altered *L. (L.) amazonensis* viability. In spite of liver toxicity, treatment with BEL was the most selective compound in vitro, as well in vivo, resulting in lower skin parasitism in the infected mice. These findings corroborate the role of PLA$_2$ in parasite virulence and maintenance in vertebrate hosts, and suggest that molecules structurally related to BEL should be considered when planning compounds against *Leishmania* sp.

**Keywords:** *Leishmania (Leishmania) amazonensis*, Macrophages, BALB/c mice, Phospholipase A$_2$, Phospholipase A$_2$ inhibitors

**Background**

The *Leishmania* parasite and its first steps of interactions with phagocytic cells have been extensively studied, mainly because the type of interaction and molecules involved determine the fate of *Leishmania*, which may be associated with death by molecules and/or cells from the host; or *Leishmania* parasites can enter in the main host’s cells, the macrophages, determining disease [1].

The initial interaction between macrophages with the *Leishmania* sp. occurs through the complement receptor (CR), mannose-fucose, fibronectin, and Fcy macrophage receptors.

Following inoculation of *Leishmania* promastigotes into the dermis of the mammalian host, a parasite metalloproteinase of 63 kDa (gp63) is able to cleave the C3b factor of the complement system into an inactive form (iC3b), which is able to bind to leishmanial lipophosphoglycan (LPG) and even to gp63. These opsonized *Leishmania* promastigotes bind to CR1 and CR3 macrophage receptors thereby commencing phagocytosis. This main type of
phagocytosis seems to impact the course of infection, since the inhibition of respiratory burst and the Th1-driven immune response create favorable conditions for Leishmania survival. Conversely, interactions between Leishmania and fibronectin receptors will trigger an inflammatory response associated with parasite death [2, 3].

Leishmanial molecules are also critical in the modulation of macrophages’ intracellular environments. LPG is one of the main glycoconjugate of Leishmania promastigotes, and is involved in the protection of the parasite not only from the acidic parasitophorous vacuoles, but also from inhibition of phagosome maturation and modulation of cytokine production. The gp63 metallo-proteinase has been credited as being a potent inhibitor of the protein kinase C pathways, which, if functioning properly, are responsible for cell proliferation, differentiation, apoptosis, and reactive oxygen and nitrogen species production; this context suggests that gp63 (in addition to LPG) has a deep impact on the modulation of leishmanicidal activity and in the establishment of leishmanial infection in macrophages [4–6]. These types of studies are extremely important for expanding the current knowledge on the physiopathology of leishmaniasis.

Although LPG and gp63 antigens have been identified as vital for parasite survival, other parasitic components are also important during the process of phagocytosis, as well as in the intracellular survival of Leishmania parasites. In this regard, it was demonstrated that the supernatant of L. (L.) amazonensis presented phospholipase A2 (PLA2) activity, and when an additional source of PLA2 was added in culture, the pathway of eicosanoid production was stimulated and prostaglandin E2 (PGE2) was produced at high levels; this was associated with increased numbers of intracellular amastigotes [7]. Moreover, in vivo studies demonstrated that PLA2-stimulated L. (L.) amazonensis induced tissue injuries when compared with the control parasite [7]. This suggests the involvement of PLA2 in the pathway of prostaglandin production, and that this pathway can be considered an additional mechanism by which L. (L.) amazonensis parasites infect, modulate inflammation and persist in the host.

Overall PGE2, a major byproduct of the metabolism of arachidonic acid, has been linked to pathology in leishmaniasis. Farrel and Kirkpatrick [8] were among the first to suggest the participation of this lipid mediator in leishmaniasis, since L. major-infected splenocytes from BALB/c mice produced elevated amounts of PGE2 and were unable to proliferate under specific stimuli. This is in contrast to splenocytes isolated from animals treated with indomethacin, a selective inhibitor of the enzyme cyclooxygenase (COX), which did not produce PGE2 and were capable of proliferating. Similarly, the human lineage of U937 macrophages presented a time-dependent elevation in the production of PGE2 following infection with L. donovani [9], and decreased after the addition of COX2 inhibitors. On the other hand, other secreted PLA2 enzymes were able to eliminate promastigote forms of L. (L.) infantum, L. (L.) amazonensis [10–12].

In order to evaluate the importance of PGE2 during experimental leishmaniasis, L. (L.) mexicana-infected BALB/c mice were treated with indomethacin. It was observed that treated animals partially controlled the size of lesions and skin parasitism parasite load the skin, a finding that was associated with reduced levels of interleukin (IL)-4, IL-10, and PGE2 in the supernatants of splenocytes [13]. These works clearly demonstrated how prostaglandin production can modulate not only the immunological response but also the outcome of parasite infection, suggesting that certain inhibitors of this complex pathway can serve as useful tools for controlling parasitism – such as the inhibitors of PLA2, which is a key enzyme responsible for triggering prostaglandin production. Thus, the main purpose of this work is to investigate the efficacy of inhibitors of cytosolic and secreted PLA2, such as bromoeno lactone (BEL), methyl arachidonyl fluorophosphonate (MAFP) and aristolochic acid (AA) during infection (in vitro and in vivo) with L. (L.) amazonensis.

Methods
Parasites
The L. (L.) amazonensis parasite (MHOM/BR/73/M2269) was kindly provided by Prof. Dr. Fernando T. Silveira from the Leishmaniasis Laboratory Prof. Dr. Ralph Laison Cryobank, Department of Parasitology, Evandro Chagas Institute, Ministry of Health, Belém, Pará, Brazil. Parasite phenotyping was identified by monoclonal antibodies and isoenzyme electrophoretic profiles (at the Leishmaniasis Laboratory of the Evandro Chagas Institute - Belém, Pará, Brazil). Parasites were grown in RPMI 1640 medium (Roswell Park Memorial Institute - Gibco®; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% heat-inactivated fetal bovine serum, 10 μg/mL of gentamicin, and 1000 U/mL of penicillin (R10) at 25 °C. Promastigote forms in the stationary phase were used.

PLA2 inhibitors
Aristolochic acid (AA) inhibits secretory PLA2, such as human synovial fluid PLA2 and PLA2 purified snake and scorpion venoms. Bromoeno lactone (BEL) is an irreversible inhibitor of calcium-independent PLA2 able to inhibit the release of arachidonate from different cell lines. Methyl arachidonyl fluorophosphonate (MAFP) is a selective and irreversible inhibitor of cytosolic PLA2 and calcium-independent PLA2.
Determination of leishmanicidal potential of PLA₂ inhibitors

Promastigote forms of \( L. (L.) \) amazonensis \((2 \times 10^6\) promastigotes/well\) were incubated in 96-well culture plates in \( R10 \) medium with bromoelol lactone (BEL) \((0.7–60 \mu M)\), methyl arachidonyl fluorophosphonate (MAFP) \((4.7–300 \mu M)\) or Aristolochic acid (AA) \((9.4–600 \mu M)\). Miltefosine was used as standard drug \((1.9–245 \mu M)\). A negative control group was cultivated in medium and dimethyl sulfoxide (DMSO) was used as a vehicle solution (never exceeding 1% v/v). The parasites were incubated for 24 h at 25 °C. Plates were washed 3 times with 200 μL of sodium chloride 0.9% (w/v) and centrifuged at 3000 rpm for 10 min at 4 °C; MTT \((3-[4,5\text{-dimethylthiazol-2-yl}]-2,5\text{-diphenyltetrazolium bromide})\) \((5.0 \text{mg/mL})\) was added for 4 h. Subsequently, 50μL of sodium dodecyl sulfate (SDS -10%) was added to each well. The plates were incubated for 18 h and read in an enzyme-linked immunosorbent assay (ELISA) reader at 595 nm. In order to access the leishmanicidal potential of PLA₂ inhibitors, 50% effective concentrations \( (\text{EC}_{50}) \) were estimated using the software GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). The \( \text{EC}_{50} \) is the concentration of the inhibitors where 50% of the host cells were unviable after the specified exposure time.

Peritoneal macrophage culture and cytotoxicity assay

Approximately \( 2 \times 10^5 \) peritoneal macrophages from BALB/c mice were cultivated in \( R10 \) medium with BEL \((0.7–60 \mu M)\), MAFP \((4.7–300 \mu M)\), AA \((9.4–600 \mu M)\) or miltefosine \((1.9–245 \mu M)\). As negative control, macrophages were cultivated in medium and DMSO (not exceeding 1% v/v). After 24 h, cell viability was analyzed by the MTT method. After evaluation of the surviving curves, non-toxic concentrations were recorded and used in further experiments. In addition, the 50% cytotoxic concentration \( (\text{CC}_{50}) \) was estimated using the software GraphPad Prism 5.0. The \( \text{CC}_{50} \) is defined as the concentration of the inhibitors where 50% of the host cells were unviable after the specified exposure time.

Effect of PLA₂ inhibitors during the interaction between the parasite and host macrophages

Promastigote forms of \( L. \) amazonensis in stationary phase were adjusted to a concentration of \( 2 \times 10^6 \) promastigotes/mL and were added to macrophage cultures (1:10 macrophage-to-parasite ratio). The co-cultures were maintained in a humidified incubator at 5% CO₂ at 35 °C. The inhibitors AA \((25.0; 50.0; 100.0 \mu M)\), BEL \((1.0; 2.0; 4.0 \mu M)\) and MAFP \((5.0; 10.0; 20.0 \mu M)\) were added to the infected cells. As standard treatment, miltefosine's \( \text{EC}_{50} \) was used [14]. After 24 h of incubation, infection indexes were estimated [15] and the concentrations able to decrease the infection index to 50% were estimated via the software GraphPad Prism 5.0.

Efficacy of PLA₂ inhibitors during experimental cutaneous leishmaniasis

Thirty male BALB/c mice were subcutaneously infected in the right hind footpad with \( 10^6 \) promastigote forms of \( L. (L.) \) amazonensis, while five BALB/c mice received sodium chloride 0.9% (w/v) via the same route (healthy group). Five weeks after infection, \( L. (L.) \) amazonensis-infected BALB/c mice were divided into six groups containing 5 animals each: groups 1 and 2 were injected with 10.0 nM \((0.012 \mu M/kg)\) and 30.0 nM \((0.036 \mu M/kg)\) of BEL, respectively. The concentration of BEL was chosen based on previous reports of animal treatment [16]; groups 3 and 4 were injected with 0.7 mM \((0.015 \mu M/kg)\) and 1.4 mM \((0.030 \mu M/kg)\) of MAFP, respectively. All these groups were treated intraperitoneally. Group 5 received Glucantime \((50 \mu M/kg)\) intralesionally. Group 6 (infected only) was injected with PBS solution. Group 7 (non-infected, non-treated animals) received only the vehicle solution (PBS control by intraperitoneal or subcutaneous routes).

Animals treated intraperitoneally were injected with 50 \( \mu L \) of PLA₂ inhibitors or PBS solution; while those treated intralesionally received 20 \( \mu L \) of Glucantime or PBS solution. Animals were injected with PLA₂ inhibitors, Glucantime or vehicle solution a total of 15 times, once a day, at 24-h intervals. The animals' physical conditions were monitored once a week. Glucantime was injected intralesionally, based on a previous work [17], and this administration route was effective at eliminating tissue amastigotes. The inhibitors BEL and MAFP were injected intraperitoneally to improve their distribution in the animal body. A group of non-infected animals were treated with BEL, MAFP or Glucantime to analyze histological alterations. One week after the last injection, the animals were anaesthetized with thiopental and sacrificed by cardiac puncture. There were no deaths prior to the endpoint, and all animals were euthanized to analyze the parasitism in the skin. Animals were not treated with AA because reports in the literature had reported its high toxicity for animals [18].

Clinical course of lesion development and determination of parasite burden on the skin and in lymph nodes

The development of lesions in the infected and treated groups was measured weekly following infection for 8 weeks. The size of the lesion was determined based on the difference between infected and uninfected footpads. The parasite loads in the skin and in lymph nodes were determined using the quantitative limiting-dilution assay, as described in [19]. Briefly, fragments from the infected footpads and lymph nodes of different groups were aseptically excised and homogenized in Schneider's...
medium. The skin and lymph node suspensions were subjected to 12 serial dilutions with four replicate wells. The number of viable parasites was determined based on the highest dilution in which the promastigotes could be grown after 10 days of incubation at 25 °C. Biopsies of the heart, lung, spleen, liver and kidney were collected and fixed in buffered 5% formalin for analysis of histopathological alterations in treated animals. These organs were collected because they are highly vascularized, which enables drugs in the bloodstream to provoke major changes and impact their physiology.

Statistical analysis
The results were expressed as the mean ± standard deviation of three independent experiments, and the nonparametric Mann-Whitney U test was used to compare the results between groups. Differences were considered statistically significant at a 5% significance level (P < 0.05). The software GraphPad Prism 5 was employed to analyze the results.

Results

Leishmanicidal and cytotoxic activities of PLA2 inhibitors

BEL was the most active PLA2 inhibitor, killing 50% of promastigote forms of *L. amazonensis* with 15.1 ± 3.7 μM; MAFP presented intermediate activity (50.5 ± 7.8 μM), followed by AA, eliminating promastigote forms with EC50 of 450.1 ± 45.6 μM; miltefosine eliminated promastigote forms with an EC50 of 12.6 ± 2.1 μM (Table 1). PLA2 inhibitors did not induce cytotoxicity to peritoneal macrophages in the tested range (Table 1). The most selective molecule was MAFP, followed by miltefosine and BEL. The lowest selectivity index was presented by AA (Table 1).

It was observed that BEL was the most active against amastigote forms and decreased the infection index by 50% at 2.6 ± 0.8 μM, followed by MAFP (17.6 ± 7.9 μM), miltefosine (21.6 ± 2.2 μM) and AA (76.9 ± 5.7 μM), as indicated in Table 1. Furthermore, it was observed that BEL was the most selective molecule, followed by MAFP, AA and finally miltefosine (Table 1).

| Compounds | EC50 (μM) | CC50 (μM) | SI | EC50 (μM) | SI |
|-----------|-----------|-----------|----|-----------|----|
| AA        | 450.1 ± 45.6 | > 600     | > 1.3 | 76.9 ± 5.7 | > 7.8 |
| BEL       | 15.1 ± 3.7 | > 60       | > 3.9 | 26.0 ± 0.8 | > 23.1 |
| MAFP      | 50.5 ± 7.8 | > 300      | > 5.9 | 17.6 ± 7.9 | > 17.0 |
| Miltefosine | 126.2 ± 2.1 | 608.0 ± 3.1 | 4.8   | 216.2 ± 2.2 | 2.8 |

The efficacies of compounds were analyzed through effective concentration 50 (EC50), and the selective indexes (SI) were estimated

* promastigote; * amastigote

Effect of PLA2 inhibitors during experimental cutaneous leishmaniasis

Infected BALB/c mice treated with 10 nM or 30 nM of the inhibitor BEL (Fig. 1a) presented smaller lesion sizes at weeks 6, 7, and 8 post-infection (P < 0.05), when compared with the infected control. In contrast, infected animals treated with 0.7 or 1.4 μM of MAFP (Fig. 1b) did not show significant alterations during the course of infection. Animals treated intraleesionally with Glucantime presented small lesion size from 6 weeks post-infection until the end of the experiment, at the 8th week (Fig. 1a and b).

In relation to skin parasitism, animals treated with 10 nM or 30 nM of BEL had fewer parasites on the skin when compared with the infected control (Fig. 1c). Infected animals treated with MAFP did not change the parasite load in the skin (Figs. 1d). Glucantime-treated animals (50 mg/kg) presented decreased parasite load when compared with the infected control group (Figs. 1c and d). Animals treated with BEL or MAFP presented lymph node parasitism similar to that in the infected control group (data not shown). Parasites were not detected in lymph nodes of Glucantime-treated animals (data not shown).

Histopathological analysis

Histological sections of the heart, liver, kidney, and spleen were analyzed to verify toxic effects of PLA2 inhibitors on BALB/c mice. Infected control animals did not present significant histopathological changes in the heart, kidney or lungs; however, in the spleen signals of germinal center activation were verified (data not shown). In the liver, some focal areas of inflammation were observed (black arrow in Fig. 2a).

Infected animals treated with MAFP did not show significant changes in analyzed organs compared with the infected control (data not shown). In comparison with infected controls, the BEL-treated group did not present signs of alterations in the heart, spleen or lungs (data not shown); however, the liver presented extensive areas of hepatocellular necrosis, as illustrated in the insets of one respective image from the group treated with 30 nM of BEL (Fig. 2b). A similar histological pattern was verified in non-infected animals treated with 30 nM of BEL (Fig. 2c). Infected and non-infected animals treated intraleesionally with Glucantime did not show changes in histological sections of analyzed organs; for comparisons, a histological liver section from an infected animal treated with 50 mg/kg of Glucantime is presented in Fig. 2d. Healthy animals did not present alterations in analyzed organs (data not shown); for comparisons a histological liver section is presented in Fig. 2e.

Discussion

In spite of classical mechanisms of innate immunity during the relation between parasite and host cells, other
components of the inflammatory process may take place during *Leishmania* infection. Recently, it was demonstrated that *L. (L.) amazonensis*-infected macrophages treated with PLA₂ presented more intracellular amastigotes when compared with the control group. Furthermore, an association between high intracellular parasitism and PGE₂ production by infected macrophages was demonstrated [7]; PGE₂ is a lipidic mediator that downregulates the respiratory burst in infected macrophages [20]. Other studies have also demonstrated a pathogenic role of the prostaglandin pathway in leishmaniasis [21]; however, to the best of our knowledge, few studies have focused on the initial enzyme responsible for triggering prostaglandin production, the PLA₂ enzyme, during experimental leishmaniasis.

Thus, in the present study, it was demonstrated that the viability of *L. (L.) amazonensis* promastigotes was altered when the PLA₂ inhibitors BEL and MAFP were added in culture. In trypanosomatids, PLA₂ plays vital roles in host cell invasion, Ca²⁺ influx, and during lipid turnover [22, 23]. Therefore, these inhibitors should affect the physiology of *L. (L.) amazonensis*, thus impacting their survival in culture, as evidenced in Table 1. In addition, *L. (L.) amazonensis* promastigotes were more sensitive to the inhibitor BEL in comparison with other treatments, and this molecule is a specific inhibitor of Ca²⁺-independent PLA₂, since 15.1 μM was able to eliminate 50% of the parasite population; followed by MAFP, an inhibitor of calcium-dependent PLA₂, that presented an EC₅₀ of 50.5 μM. These data suggest that Ca²⁺...
*"-independent PLA2 may hold vital biological significance for the survival of parasites, such that molecules able to target these enzymes can be considered valuable prototype drugs. Moreover, the activities of these inhibitors on the parasites seems to be specific, since macrophages incubated with these same inhibitors, at the same range of concentrations, did not show significant alterations in their viability, suggesting that the inhibitors are more selective to the parasite than to the host cells.

In order to verify whether PLA2 inhibitors can impact the survival of intracellular amastigotes, L. (L.) amazonensis-infected macrophages were treated with BEL, MAFP and AA. In this case, both BEL and MAFP inhibitors were able to decrease the intracellular parasitism, suggesting that different families of PLA2 enzymes not only may play some role during the infection, but also might be important for the intracellular survival of amastigote forms. Possibly PLA2s (from host and parasites) may favor the production of PGE2, which is suppressive for macrophages [24, 25], as demonstrated in different studies [7, 9, 26, 27]. In the other hand, AA was shown to be the least active of all inhibitors assayed, despite presenting an intermediate selectivity index. Other PLA2 inhibitors – such as quinacrine, 4-bromophenacyl bromide and phenetermine – were used during the interaction of Trypanosoma cruzi and macrophages. In this case it was observed that the inhibitors suppressed parasite surface binding on the host cell and internalization [28], suggesting that PLA2 presents a role during intracellular infections, and thus can be used as a molecular target for designing new leishmanicidal molecules.

Given that the inhibitors BEL and MAFP were able to decrease the intracellular parasitism into host macrophages, in vivo experiments were carried out to verify whether PLA2 could be considered a molecular target to characterize new prototype drugs. In this aspect, it was verified that BALB/c mice infected with L. (L.) amazonensis and treated with 10 nM or 30 nM of BEL exhibited decreased lesion size at 6, 7, and 8 weeks post-infection when compared with the infected control, an effect associated with reduced parasitism on the skin, but not in the lymph nodes (data not shown), suggesting that in vivo PLA2 may be responsible, at least in part, for the induction of pathology in a murine model of cutaneous leishmaniasis. On the other hand, animals treated with MAFP did not show significant alterations in the course of infection. The inhibitor AA was not assayed in vivo due to its toxicity for animals [14].

In the cellular environment, PLA2 enzymes catalyze the hydrolysis of phospholipid sn-2 ester bond from cell membranes. This reaction is the primary pathway that allows the release of arachidonic acid. Following this biochemical step, the enzyme cyclooxygenase converts arachidonic acid into different classes of prostaglandins, according to the available enzymes associated with eicosanoid production. In leishmaniasis some studies demonstrated that this pathway is correlated with disease worsening; on the other hand, the use of inhibitors or commercial available drugs able to interfere with enzymes pertaining to this pathway can suppress the production of prostaglandins, thus improving the lesions. In this respect, Pérez-Santos and collaborators [13] showed that the treatment of L. (L.) mexicana-infected BALB/c mice with indomethacin, a selective inhibitor of COX enzymes, was able to restrain skin and lymph node parasitism; moreover, treated animals presented increased amounts of Th1 interleukins [13, 29]. Therefore, the blockage of enzymes belonging to this pathway can improve the outcome of infection. Given that PLA2 is the first step in triggering eicosanoid production, it should be considered an interesting molecular target for designing new therapeutic molecules.

In spite of these positive findings, the inhibitor BEL was toxic to the liver of infected BALB/c mice as well as their non-infected counterparts, as demonstrated in histological sections, where degenerated hepatocytes (inset) and necrotic areas were identified. A previous work demonstrated that although BEL was not toxic to peritoneal macrophages, but the constant inhibition of PLA2 in the neurons resulted in a long-term loss of neuronal viability, suggesting that in some organs, (such as the liver), preserving the activity of PLA2 is essential for maintaining host cell viability and homeostasis [30]. This study also opens future perspectives to use BEL inhibitor as an intralesional treatment, which in turn could reduce liver toxicity.

Despite the toxicity presented by BEL, the relevance of PLA2 during the infection was also demonstrated. Furthermore, although BALB/c mice did not clear the L. (L.) amazonensis infection following the BEL treatment, these results suggested that PLA2 might represent a potential target for inhibiting Leishmania infection. However, the main challenge is to find or design effective and non-toxic PLA2 inhibitors that are able to block the entry or survival of the leishmania parasites in host cells.

**Conclusions**

Taken together, our results demonstrated that promastigote and intracellular amastigotes (in vitro and in vivo) of L. (L.) amazonensis are more sensitive to BEL inhibitor compared with other inhibitors, and that molecules structurally correlated with BEL might serve as an interesting alternative for designing new prototypes directed against Leishmania parasites.

**Abbreviations**

- %: Percentage; °C: Celsius; AA: Arachidonic acid; BEL: Bromoenoil lactone; COX: Cyclooxygenase; CR: Complement receptor; CR1 and CR3: Complement receptors 1 or 3, respectively; ELISA: Enzyme-linked immunosorbent assay; gp63: Metalloproteinase of 63 kDa; IC3b: Inactive form of C3b fragment; IL: Interleukin; kDa: Kilo Dalton; kg: Kilogram; L: Leishmania; LPG: Lipophosphoglycan; MAFP: Methyl arachidonyl fluorophosphonate;
Availability of data and materials
The datasets used during the current study are available from the corresponding author on request.

Authors’ contributions
Formal analysis: MLACB, LFDP. Investigation: MLACB, LFDP. Methodology: MLACB, LFDP. Writing: LFDP, MDL, MHT. All authors read and approved the final manuscript.

Ethics approval
Animal experiments were carried out using protocols approved by the Ethics Committee for Animal Experimentation of São Paulo University under the number CEP 067/1.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Laboratory of Pathology of Infectious Diseases (LIM-50), Medical School, University of São Paulo (USP), Av. Dr. Arnaldo, 455, São Paulo, SP CEP 01246-903, Brazil. 2. Pathology Department, Case Western Reserve University, 2103 Cornell Rd, room 5503, Cleveland, OH 44106, USA. 3. São Paulo State University (UNESP), Institute of Biosciences, São Vicente, Praça Infante Dom Henrique, s/n, 11380-900 São Vicente, SP, Brazil. 4. School of Dentistry, Camilo Castelo Branco University (Unicastrolo), Rua Carolina Fonseca, 584, São Paulo, SP CEP 08230-030, Brazil.

Received: 2 March 2018 Accepted: 1 August 2018

Published online: 27 August 2018

References
1. de Morais CGV, Castro Lima AK, Terra R, dos Santos RF, Da-Silva SAG, PML D. The dialogue of the host-parasite relationship: Leishmania spp and Trypanosoma cruzi infection. Biomed Res Int. 2015;2015:324915.
2. Arango Duque G, Descoteaux A. Leishmania survival in the macrophage: where the ends justify the means. Curr Opin Microbiol. 2015;26:32–40.
3. Podinovskaia M, Descoteaux A. Leishmania and the macrophage: a multifaceted interaction. Future Microbiol. 2015;10(1):111–29.
4. Olivier M, Gregory DJ, Forger G. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev. 2005;18(2):293–305.
5. Forestier CL, Gao Q, Boons GJ. Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate? Front Cell Infect Microbiol. 2014;4:193.
6. Passero LFD, Assis RR, da Silva TNF, Noqueira PM, Macedo DH, Pessoa NL, et al. Differential modulation of macrophage response elicited by glycoinositolphospholipids and lipophosphoglycan from Leishmania (Viannia) shawi. Parasitol Int. 2015;64(4):32–5.
7. Passero LFD, Laurenti MD, Tomokane TY, Corbett CEP, Toyama MH. The effect of phospholipase A2 from Crotalus durissus clavilineus on Leishmania (Leishmania) amazonensis infection. Parasitol Res. 2008;102(5):1025–33.
8. Farrell JP, Kirkpatrick CE. Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major–infected BALB/c mice. J Immunol. 1987;138(3):902–7.
9. Matte C, Maion G, Mourad W, Olivier M. Leishmania donovani–induced macrophages cyclooxygenase-2 and prostaglandin E2 synthesis. Parasite Immunol. 2001;23(4):177–84.
10. Barros GAC, Pereira AV, Barros LC, Lourenço A J, Calvi SA, Santos LD, et al. In vitro activity of phospholipase A2 and of peptides from Crotalus durissus terrificus venom against amastigote and promastigote forms of Leishmania (L.) infantum chagasi. J Venom Anim Toxins incl Trop Dis. 2015;21:48. https://doi.org/10.1186/s40409-015-0049-0.
11. Terra ALC, Moreira-Dill LS, Simões-Silva R, Monteiro JRN, Cavalcante WLG, Gallacci M, et al. Biological characterization of the Amazon coral Micrurus spixi snake venom: isolation of a new neurotoxic phospholipase A2. Toxicon. 2015;103:1–11.
12. Pereira A, de Barros G, Pinto EG, Tempone AG, de Oliveira Oni R, dos Santos LD, et al. Melittin induces in vitro death of Leishmania (Leishmania) infantum by triggering the cellular innate immune response. J Venom Anim Toxins incl Trop Dis. 2016;22:1; https://doi.org/10.1186/s40409-016-0055-x.
13. Pérez-Santos JL, Talamás-Rohana P. In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunol. 2001;23(1):599–606.
14. Bezerra-Souza A, Yamamoto ES, Laurenti MD, Ribeiro SP, Passero LF. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Parasitol Int. 2016;65(6 Pt A):702–7.
15. Passero LF, Sacomon JV, Tomokane TY, Corbett CEP, da Silveira FT, Laurenti MD. Ex vivo and in vivo biological behaviour of Leishmania (Viannia) shawi. Parasitol Res. 2009;105(6):1741–7.
16. Yeo JF, Ong WY, Ling SF, Farooqui AA. Intracerebroventricular injection of phospholipases A2 inhibitors modulates alodynia after facial carrageenan injection in mice. Pain. 2004;112(1–2):148–55.
17. Yamamoto ES, Campos BLS, Jesus JA, Laurenti MD, Ribeiro SP, Kallas EG, et al. The effect of ursolic acid on Leishmania (Leishmania) amazonensis is related to programmed cell death and presents therapeutic potential in experimental cutaneous leishmaniasis. PLoS One. 2015;10(1):e0124888.
18. Shi M, Ma L, Zhou L, Fu P. Renal protective effects of 17β-estradiol on mice with acute aristolochic acid nephropathy. Molecules. 2016;21(10):1391.
19. Campos BLS, Silva TN, Ribeiro SP, Carvalho KL, Kallas EG, Laurenti MD, et al. Analysis of iron superoxide dismutase–encoding DNA vaccine on the evolution of the Leishmania amazonensis experimental infection. Parasite Immunol. 2015;37(8):407–16.
20. Serezzati CH, Chung J, Ballinger MN, Moore BB, Aronoff DM, Peters-Golden M. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol. 2007;37(5):562–70.
21. Arcano AF, LaRocque-de-Freitas IR, Rocha JDB, Zarnith D, Costa-da-Silva AC, Nunes MP, et al. The PGEl2l–10 axis determines susceptibility of B–1 cell–derived phagocytes (B–1CDP) to Leishmania major infection. PLoS One. 2015;10(5):e0124888.
22. Oppendoes FR, van Roy J. The phospholipases of Trypanosoma brucei bloodstream forms and cultured procyclics. Mol Biochem Parasitol. 1982;53:309–19.
23. Bieuverin DL, Lennert J, den Drijver R, Bielefeldt--Olson B. Arginase I, polyamine, and prostaglandin E2 pathways with acute aristolochic acid nephropathy. Molecules. 2016;21(10):1391.
24. Tsuchida K, Ibuki T, Matsumura K. Bromoenol lactone, an inhibitor of prostaglandin E2 synthesis. Parasite Immunol. 2001;23(4):177–84.
25. Bhattacharjee A, Majumder S, Ghosh S, Biswas S, Majumdar S. Leishmania donovani–induced prostaglandin E2 generation is critically dependent on host toll-like receptor 2-cytosolic phospholipase A2 signaling. Infect Immun. 2016;84(10):2963–73.
28. Connelly MC, Kierszenbaum F. Modulation of macrophage interaction with Trypanosoma cruzi by phospholipase A\textsubscript{2}-sensitive components of the parasite membrane. Biochem Biophys Res Commun. 1984;121(3):931–9.

29. Li J, Padigel UM, Scott P, Farrell JP. Combined treatment with interleukin-12 and indomethacin promotes increased resistance in BALB/c mice with established Leishmania major infections. Infect Immun. 2002;70(10):5715–20.

30. Mendes CT, Gattaz WF, Schaeffer EL, Forlenza OV. Modulation of phospholipase A\textsubscript{2} activity in primary cultures of rat cortical neurons. J Neural Transm (Vienna). 2005;112(10):1297–308.